Trump Administration’s Pharmaceutical Deals Signal Major Policy Shift in Drug Pricing
Pharmaceutical giants Pfizer and AstraZeneca have reached landmark agreements with the Trump Administration, committing to significant drug price reductions and substantial domestic investments. The deals, reportedly negotiated under tariff pressure, represent a new approach to pharmaceutical policy that ties affordability to manufacturing reshoring.
Pharmaceutical Giants Yield to Administration Pressure
Two major pharmaceutical companies have reached significant agreements with the Trump Administration that analysts suggest could reshape how drug pricing is approached in the United States. According to reports, both Pfizer and AstraZeneca agreed to substantial price reductions and domestic investment commitments under a new framework that links affordability to manufacturing reshoring.
